Skip to main content

Neutropenia

8
Pipeline Programs
7
Companies
10
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
3
2
2
0
0
1
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
1100%
+ 11 programs with unclassified modality

Competitive Landscape

7 companies ranked by most advanced pipeline stage

Astellas
AstellasChina - Shenyang
1 program
1
MicafunginPhase 41 trial
Active Trials
NCT01135589Unknown145Est. May 2012
MSD
MSDIreland - Ballydine
2 programs
1
1
caspofungin acetatePhase 21 trial
Posaconazole IV solutionPhase 11 trial
Active Trials
NCT02452034Completed118Est. Sep 2018
NCT00082537Completed100Est. Oct 2006
Sharp Therapeutics
Sharp TherapeuticsPA - Pittsburgh
2 programs
1
1
caspofungin acetatePhase 2
Posaconazole IV solutionPhase 1
Pfizer
PfizerNEW YORK, NY
3 programs
1
2
AnidulafunginPhase 1/21 trial
VoriconazolePhase 1/2Small Molecule1 trial
HSP-130Phase 12 trials
Active Trials
NCT02650193Completed25Est. Oct 2017
NCT02629289Completed153Est. Jun 2016
NCT00056381Completed25Est. Jun 2004
+1 more trials
X4 Pharmaceuticals
2 programs
MavorixaforPHASE_1_21 trial
MavorixaforPHASE_31 trial
Active Trials
NCT04154488Completed32Est. Aug 2024
NCT06056297Recruiting176Est. Nov 2027
Allergy Therapeutics
Allergy TherapeuticsUK - West Sussex
1 program
A Randomized, Open Label, Comparative, Multicenter Trial of Voriconazole Vs. AmBisome for Empirical N/A1 trial
Active Trials
NCT00008840Completed866Est. Nov 2005
Merck & Co.
Merck & Co.RAHWAY, NJ
1 program
caspofungin acetatePHASE_2

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
AstellasMicafungin
X4 PharmaceuticalsMavorixafor
PfizerHSP-130
MSDcaspofungin acetate
X4 PharmaceuticalsMavorixafor
PfizerAnidulafungin
PfizerVoriconazole
MSDPosaconazole IV solution
PfizerHSP-130
Allergy TherapeuticsA Randomized, Open Label, Comparative, Multicenter Trial of Voriconazole Vs. AmBisome for Empirical

Clinical Trials (10)

Total enrollment: 1,689 patients across 10 trials

Micafungin Prevention Study for Fungal Disease in Child Receiving Allogenic Hematopoietic Stem Cell Transplantation

Start: Apr 2010Est. completion: May 2012145 patients
Phase 4Unknown

A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections

Start: Jun 2024Est. completion: Nov 2027176 patients
Phase 3Recruiting

A Study Of The Safety And Effects Of One Or More Doses Of HSP-130 Injected Under The Skin In Women With Breast Cancer That Has Not Spread To Distant Sites In The Body.

Start: Dec 2015Est. completion: Oct 201725 patients
Phase 2Completed
NCT00082537MSDcaspofungin acetate

MK0991 Versus Amphotericin B for Empirical Therapy in Febrile, Neutropenic Pediatric Patients (0991-044)

Start: Apr 2004Est. completion: Oct 2006100 patients
Phase 2Completed

A Study of Mavorixafor in Participants With Congenital Neutropenia and Chronic Idiopathic Neutropenia Disorders

Start: Oct 2021Est. completion: Aug 202432 patients
Phase 1/2Completed
NCT00056381PfizerAnidulafungin

Safety, Tolerance and Pharmacokinetics of Anidulafungin in Immunocompromised Children Ages 2-17

Start: Jul 2003Est. completion: Jun 200425 patients
Phase 1/2Completed
NCT00174473PfizerVoriconazole

A Study to Investigate the Pharmacokinetics, Safety and Tolerability of Voriconazole in Children

Start: Jun 2003Est. completion: Aug 200549 patients
Phase 1/2Completed
NCT02452034MSDPosaconazole IV solution

Safety and Pharmacokinetics of Intravenous and Oral Posaconazole in Immunocompromised Children (MK-5592-097)

Start: Sep 2015Est. completion: Sep 2018118 patients
Phase 1Completed

A Comparative Study to Evaluate the Effect of HSP-130, US-approved Neulasta and EU-approved Neulasta in Healthy Participants

Start: Aug 2015Est. completion: Jun 2016153 patients
Phase 1Completed
NCT00008840Allergy TherapeuticsA Randomized, Open Label, Comparative, Multicenter Trial of Voriconazole Vs. AmBisome for Empirical

A Randomized, Open Label, Comparative, Multicenter Trial of Voriconazole Vs. AmBisome for Empirical Antifungal Therapy in Immunocompromised Patients With Persistent Fever and Neutropenia

Est. completion: Nov 2005866 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 actively recruiting trials targeting 1,689 patients
7 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.